HomeCONGRESSInternational Congresses

International Congresses

View Category
Antiplatelet

ESC 2018 | ARRIVE: Aspirin in the Eye of the Storm of Primary Prevention

Aspirin failed to reach the primary endpoint in a population that was at risk of experiencing cardiovascular...
solaci -
Learn More
Other

ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction

This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction...
solaci -
Learn More
Antiplatelet

ESC 2018 | ASCEND: Aspirin for Primary Prevention in Diabetic Patients Fails the Cost-Benefit Analysis

The obvious risk of bleeding posed by aspirin was too clear in this work, casting a shadow...
solaci -
Learn More
Acute coronary syndromes

ESC 2018 | CULPRIT-SHOCK: 1-Year Results Continue to Support Treatment of the Culprit Artery Only

Increases in the rates of revascularization and heart failure do not justify the early mortality advantage shown...
solaci -
Learn More
Acute coronary syndromes

ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access

Transradial access should be the access of choice in patients with acute coronary syndrome, while bivalirudin has...
solaci -
Learn More
Antithrombotic Anticoagulants

ESC 2018 | MARINER: Rivaroxaban as Thromboprophylaxis after Hospitalization

For acute patients hospitalized for a clinical disease (e.g.: heart failure), indicating rivaroxaban for 6.5 weeks after...
solaci -
Learn More
Chronic Ischemic cardiopathy

ESC 2018 | FUTURE: A Thorn in FFR and More Questions than Answers

As observed at the preliminary analysis that motivated the FUTURE trial early termination, the use of fractional...
solaci -
Learn More
Structural heart disease

ESC 2018 | FRANCE-TAVI: Atrial Fibrillation and Anticoagulation Associated to Mortality in TAVR

Some of the many ongoing randomized studies including patients with atrial fibrillation (AF) might finally answer the...
solaci -
Learn More